OmniAb

Historical price data

OmniAb operates as a pure-play antibody discovery platform, licensing its proprietary transgenic animal technologies to over 100 biopharmaceutical partners worldwide. Its core strategy is to generate recurring, non-dilutive revenue through upfront fees, research funding, and, most significantly, downstream milestones and royalties on partnered programs that advance into clinical development and commercialization. The company's key achievement is establishing a broad and deep partner network, with numerous programs derived from its technology now in clinical trials, validating the platform's ability to generate high-quality drug candidates.

A comprehensive suite of proprietary transgenic animal systems (OmniRat, OmniMouse, OmniChicken, OmniFlic, OmniClic, Omni dAb, OmniUltra) designed to generate diverse, fully human antibodies, bispecifics, single-domain antibodies, and peptides through in vivo immune responses.

OmniAb competes with other discovery platform firms like AbCellera (in vitro/microfluidics) and BioNTech, as well as large CROs. Its key advantages are the breadth of its in vivo transgenic platforms, a validated track record with a recent drug approval, and a collaborative partnership model. The primary competitive threat is technological disruption from computational design methods.